GENFIT: We firmly stand behind elafibranor’s strategy, despite minor delays due to the Covid-19 | BUY - TOP PICKS | EUR60 vs. EUR65 (+298%)
GENFIT - BUY - TOP PICKS | EUR60 vs. EUR65 (+298%)We firmly stand behind elafibranor’s strategy, despite minor delays due to the Covid-19
Covid-19 will cause some delays for filing
No more details about the new secondary endpoint
FV decreased to EUR60 vs EUR65 – Buy reiterated
Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.